D4V has joined the Series A extension round of Dioseve Inc., a biotechnology startup developing products for assisted reproductive medicine using induced pluripotent stem cell (iPS cell) technology.

Dioseve is developing ReproNest, a product designed to support the in vitro maturation (IVM) of immature eggs using iPS cell-derived ovarian support-like cells. By improving the egg maturation process, the company aims to reduce the physical, emotional, and financial burdens associated with conventional IVF treatments, including hormone stimulation and frequent clinic visits, while expanding options for fertility treatment and preservation.

D4V looks forward to supporting Dioseve as it works to bring its innovative technology into clinical practice, with the goal of reducing patient burdens and expanding reproductive healthcare options.

Learn more about Dioseve at https://dioseve.com/en/